ACC1 is overexpressed in liver cancers and contributes to the proliferation of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A

Ye,Bingyu; Yin,Li; Wang,Qiwen; Xu,Cunshuan

doi:10.3892/mmr.2019.9994

ACC1 is overexpressed in liver cancers and contributes to the proliferation of human hepatoma Hep G2 cells and the rat liver cell line BRL 3A

Authors:
- Bingyu Ye
- Li Yin
- Qiwen Wang
- Cunshuan Xu
View Affiliations

Affiliations: State Key Laboratory Cultivation Base for Cell Differentiation Regulation, College of Life Science, Henan Normal University, Xinxiang, Henan 453007, P.R. China
Published online on: February 27, 2019 https://doi.org/10.3892/mmr.2019.9994
Pages: 3431-3440
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acetyl‑coenzyme A carboxylase 1 (ACC1) serves a major role in fatty acid synthesis. Previous reports have indicated that ACC1 is a promising drug target for treating human diseases, particularly cancers and metabolic diseases; however, the role of ACC1 in liver cancer and normal liver function remains unknown. In the present study, bioinformatics analysis indicated that ACC1 is overexpressed in liver cancer. Kaplan‑Meier survival analysis revealed that the expression levels of ACC1 are highly associated with the prognosis of patients with liver cancer. To determine the role of ACC1 in cancer and normal liver cells, ACC1 expression was downregulated in human hepatoma Hep G2 cells and the rat liver cell line BRL 3A using RNA interference technology, which demonstrated that silencing of ACC1 significantly suppressed the cell viability in the two cell lines. Additionally, ACC1 knockdown decreased the mRNA and protein expression levels of the cell proliferation‑associated genes MYCN, JUN, cyclin D1 (CCND1) and cyclin A2 (CCNA2) in BRL 3A. Furthermore, the number of cells in division phase (G2/M) was significantly reduced in the interference group, as detected by flow cytometry. Thus, ACC1 may bind and activate CCNA2, CCND1, MYCN and JUN to promote BRL 3A proliferation. In summary, the results of present study indicated that overexpression of ACC1 is significantly associated with the survival time of patients with liver cancer, and may provide insight into the association between ACC1 and cell proliferation in BRL 3A cells.

View Figures

View References

1	Harwood HJ Jr: Treating the metabolic syndrome: Acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets. 9:267–281. 2005. View Article : Google Scholar : PubMed/NCBI
2	Kim KH: Regulation of mammalian acetyl-coenzyme A carboxylase. Annu Rev Nutr. 17:77–99. 1997. View Article : Google Scholar : PubMed/NCBI
3	McGarry JD, Mannaerts GP and Foster DW: A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 60:265–270. 1977. View Article : Google Scholar : PubMed/NCBI
4	Nugteren DH: The enzymic chain elongation of fatty acids by rat-liver microsomes. Biochim Biophys Acta. 106:280–290. 1965. View Article : Google Scholar : PubMed/NCBI
5	Munday MR: Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans. 30:1059–1064. 2002. View Article : Google Scholar : PubMed/NCBI
6	Saggerson D: Malonyl-CoA, a key signaling molecule in mammalian cells. Annu Rev Nutr. 28:253–272. 2008. View Article : Google Scholar : PubMed/NCBI
7	Glatzel DK, Koeberle A, Pein H, Löser K, Stark A, Keksel N, Werz O, Muller R, Bischoff I and Fürst R: Acetyl-CoA carboxylase 1 regulates endothelial cell migration by shifting the phospholipid composition. J Lipid Res. 59:298–311. 2018. View Article : Google Scholar : PubMed/NCBI
8	Brusselmans K, De Schrijver E, Verhoeven G and Swinnen JV: RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 65:6719–6725. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jones JE, Esler WP, Patel R, Lanba A, Vera NB, Pfefferkorn JA and Vernochet C: Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) reduces proliferation and de novo lipogenesis of EGFRvIII human glioblastoma cells. PLoS One. 12:e01695662017. View Article : Google Scholar : PubMed/NCBI
10	Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, Lenoir GM and Venezia ND: BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene. 21:6729–6739. 2002. View Article : Google Scholar : PubMed/NCBI
11	Chajes V, Cambot M, Moreau K, Lenoir GM and Joulin V: Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 66:5287–5294. 2006. View Article : Google Scholar : PubMed/NCBI
12	Abu-Elheiga L, Matzuk MM, Abo-Hashema KA and Wakil SJ: Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 291:2613–2616. 2001. View Article : Google Scholar : PubMed/NCBI
13	Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK, Westlin WF, Kapeller R and Harwood HJ Jr: Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci USA. 113:E1796–E1805. 2016. View Article : Google Scholar : PubMed/NCBI
14	Harwood HJ Jr: Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. Curr Opin Investig Drugs. 5:283–289. 2004.PubMed/NCBI
15	Schreurs M, van Dijk TH, Gerding A, Havinga R, Reijngoud DJ and Kuipers F: Soraphen, an inhibitor of the acetyl-CoA carboxylase system, improves peripheral insulin sensitivity in mice fed a high-fat diet. Diabetes Obes Metab. 11:987–991. 2009. View Article : Google Scholar : PubMed/NCBI
16	Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
17	Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI
18	Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, Martínez-Torteya A, Chacolla-Huaringa R, Rodriguez- Barrientos A, Tamez-Peña JG and Treviño V: SurvExpress: An online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 8:e742502013. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Boncler M, Różalski M, Krajewska U, Podsędek A and Watala C: Comparison of PrestoBlue and MTT assays of cellular viability in the assessment of anti-proliferative effects of plant extracts on human endothelial cells. J Pharmacol Toxicol Methods. 69:9–16. 2014. View Article : Google Scholar : PubMed/NCBI
21	Bouchard C, Staller P and Eilers M: Control of cell proliferation by Myc. Trends Cell Biol. 8:202–206. 1998. View Article : Google Scholar : PubMed/NCBI
22	Miquet JG, Freund T, Martinez CS, Gonzalez L, Diaz ME, Micucci GP, Zotta E, Boparai RK, Bartke A, Turyn D and Sotelo AI: Hepatocellular alterations and dysregulation of oncogenic pathways in the liver of transgenic mice overexpressing growth hormone. Cell Cycle. 12:1042–1057. 2013. View Article : Google Scholar : PubMed/NCBI
23	Morello D, Lavenu A and Babinet C: Differential regulation and expression of jun, c-fos and c-myc proto-oncogenes during mouse liver regeneration and after inhibition of protein synthesis. Oncogene. 5:1511–1519. 1990.PubMed/NCBI
24	Pauklin S and Vallier L: The cell-cycle state of stem cells determines cell fate propensity. Cell. 155:135–147. 2013. View Article : Google Scholar : PubMed/NCBI
25	Nelsen CJ, Rickheim DG, Timchenko NA, Stanley MW and Albrecht JH: Transient expression of cyclin D1 is sufficient to promote hepatocyte replication and liver growth in vivo. Cancer Res. 61:8564–8568. 2001.PubMed/NCBI
26	Rickheim DG, Nelsen CJ, Fassett JT, Timchenko NA, Hansen LK and Albrecht JH: Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology. 36:30–38. 2002. View Article : Google Scholar : PubMed/NCBI
27	Mateyak MK, Obaya AJ and Sedivy JM: c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 19:4672–4683. 1999. View Article : Google Scholar : PubMed/NCBI
28	Carroll JS, Swarbrick A, Musgrove EA and Sutherland RL: Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: Implications for the antiproliferative effects of antiestrogens. Cancer Res. 62:3126–3131. 2002.PubMed/NCBI
29	Daksis JI, Lu RY, Facchini LM, Marhin WW and Penn LJ: Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene. 9:3635–3645. 1994.PubMed/NCBI
30	Perez-Roger I, Kim SH, Griffiths B, Sewing A and Land H: Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 18:5310–5320. 1999. View Article : Google Scholar : PubMed/NCBI
31	Oswald F, Lovec H, Möröy T and Lipp M: E2F-dependent regulation of human MYC: Trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene. 9:2029–2036. 1994.PubMed/NCBI
32	Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK and Fausto N: Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med. 205:91–103. 2008. View Article : Google Scholar : PubMed/NCBI
33	Herber B, Truss M, Beato M and Müller R: Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 9:1295–1304. 1994.PubMed/NCBI
34	Musgrove EA, Lee CS, Buckley MF and Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA. 91:8022–8026. 1994. View Article : Google Scholar : PubMed/NCBI
35	Gong D, Pomerening JR, Myers JW, Gustavsson C, Jones JT, Hahn AT, Meyer T, Meyer T and Ferrell JE Jr: Cyclin A2 regulates nuclear-envelope breakdown and the nuclear accumulation of cyclin B1. Curr Biol. 17:85–91. 2007. View Article : Google Scholar : PubMed/NCBI
36	Garnier D, Loyer P, Ribault C, Guguen-Guillouzo C and Corlu A: Cyclin-dependent kinase 1 plays a critical role in DNA replication control during rat liver regeneration. Hepatology. 50:1946–1956. 2009. View Article : Google Scholar : PubMed/NCBI
37	Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and Thompson CB: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
38	Zhan Y, Ginanni N, Tota MR, Wu M, Bays NW, Richon VM, Kohl NE, Bachman ES, Strack PR and Krauss S: Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin Cancer Res. 14:5735–5742. 2008. View Article : Google Scholar : PubMed/NCBI
39	Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70:8117–8126. 2010. View Article : Google Scholar : PubMed/NCBI
40	Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, et al: Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 22:1108–1119. 2016. View Article : Google Scholar : PubMed/NCBI
41	Hasslacher M, Ivessa AS, Paltauf F and Kohlwein SD: Acetyl-CoA carboxylase from yeast is an essential enzyme and is regulated by factors that control phospholipid metabolism. J Biol Chem. 268:10946–10952. 1993.PubMed/NCBI
42	Al-Feel W, DeMar JC and Wakil SJ: A Saccharomyces cerevisiae mutant strain defective in acetyl-CoA carboxylase arrests at the G2/M phase of the cell cycle. Proc Natl Acad Sci USA. 100:3095–3100. 2003. View Article : Google Scholar : PubMed/NCBI
43	Savage DB, Choi CS, Samuel VT, Liu ZX, Zhang D, Wang A, Zhang XM, Cline GW, Yu XX, Geisler JG, et al: Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest. 116:817–824. 2006. View Article : Google Scholar : PubMed/NCBI
44	Abu-Elheiga L, Matzuk MM, Kordari P, Oh W, Shaikenov T, Gu Z and Wakil SJ: Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA. 102:12011–12016. 2005. View Article : Google Scholar : PubMed/NCBI